EUVIMEDEUVIMED entdecken
Vergleichsstudie

Real-World Effectiveness and Safety of Recombinant Human Growth Hormone in Chinese Children with Noonan Syndrome: Long-Term Follow-Up and a 2-Year Comparison of Short- and Long-Acting Formulations

Xinying Gao, Jiajia Chen, Beibei Zhang, Manman Zhao, Yaguang Peng, Chunxiu Gong

Hormone and Metabolic Research · 01.09.2026 · 58 (09) · 380-386

DOI: 10.1055/a-2900-8976 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.09.2026. Verfasst von Xinying Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Geriatric Hospital, Department of Pediatrics, China, Beijing. Hauptthemen laut MEDLINE: Human Growth Hormone, Noonan Syndrome, Recombinant Proteins. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This retrospective real-world cohort study evaluated the effectiveness and safety of recombinant human growth hormone therapy in Chinese children with Noonan syndrome, with a predefined comparison between short-acting growth hormone and long-acting growth hormone during the first 2 years of treatment. Twenty children with Noonan syndrome were included; 16 were boys, and the median age at recombinant human growth hormone initiation was 5.55 years. The baseline height standard deviation score was−3.01. During the first 2 years, 10 patients received short-acting growth hormone and 10 patients received long-acting growth hormone. The median height standard deviation score increased to−2.20 after 1 year and−1.84 after 2 years, with significant longitudinal improvement over time. The cumulative change in height standard deviation score did not differ significantly between short-acting growth hormone and long-acting growth hormone at year 1 (0.58 vs. 0.71) or year 2 (1.01 vs. 1.30). First-year growth velocity was comparable between groups, whereas the apparent second-year difference was no longer significant after excluding short-acting growth hormone-treated patients who entered puberty and received adjunctive therapy. Among 16 patients with PTPN11 variants, the median cumulative change in height standard deviation score was 1.20 and 56.3% achieved an HtSDS of above−2 standard deviation score at the last follow-up. No diabetes mellitus, malignancy, new cardiovascular events, intracranial hypertension, or slipped capital femoral epiphysis occurred. Insulin-like growth factor-1 standard deviation score elevations were transient. Recombinant human growth hormone therapy was associated with sustained linear growth in children with Noonan syndrome, and short-acting growth hormone and long-acting growth hormone showed broadly comparable short-term efficacy under regular safety monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneNoonan SyndromeRecombinant ProteinsAdolescentChildChild, PreschoolFemaleHumansMaleBody HeightChinaFollow-Up StudiesRetrospective StudiesTreatment OutcomeEast Asian People

Substanzen

Human Growth HormoneRecombinant Proteins

Autor:innen und Institutionen

  • Beijing Geriatric Hospital, Department of Pediatrics, China, Beijing.
  • Beijing Children's Hospital, Capital Medical University, Department of Endocrinology, Genetics and Metabolism, China, Beijing.
  • Beijing Luhe Hospital, Department of Pediatrics, China, Beijing.
  • Beijing Children's Hospital, Capital Medical University, Center for Clinical Epidemiology and Evidence-based Medicine, China, Beijing.

Zitieren

APA

Gao, X., Chen, J., Zhang, B., Zhao, M., Peng, Y., & Gong, C. (2026). Real-World Effectiveness and Safety of Recombinant Human Growth Hormone in Chinese Children with Noonan Syndrome: Long-Term Follow-Up and a 2-Year Comparison of Short- and Long-Acting Formulations. Hormone and Metabolic Research, 58(09), 380-386. https://doi.org/10.1055/a-2900-8976

Vancouver

Gao X, Chen J, Zhang B, Zhao M, Peng Y, Gong C. Real-World Effectiveness and Safety of Recombinant Human Growth Hormone in Chinese Children with Noonan Syndrome: Long-Term Follow-Up and a 2-Year Comparison of Short- and Long-Acting Formulations. Hormone and Metabolic Research. 2026;58(09):380-386. doi:10.1055/a-2900-8976

BibTeX
@article{Gao2026,
  author = {Gao, Xinying and Chen, Jiajia and Zhang, Beibei and Zhao, Manman and Peng, Yaguang and Gong, Chunxiu},
  title = {Real-World Effectiveness and Safety of Recombinant Human Growth Hormone in Chinese Children with Noonan Syndrome: Long-Term Follow-Up and a 2-Year Comparison of Short- and Long-Acting Formulations},
  journal = {Hormone and Metabolic Research},
  year = {2026},
  volume = {58},
  number = {09},
  pages = {380--386},
  doi = {10.1055/a-2900-8976}
}
Kostenlos starten →